140 related articles for article (PubMed ID: 15134176)
1. Lamivudine-resistant hepatitis B virus and ongoing lamivudine therapy: stop the merry-go-round, it's time to get off!
Angus P; Locarnini S
Antivir Ther; 2004 Apr; 9(2):145-8. PubMed ID: 15134176
[No Abstract] [Full Text] [Related]
2. Mutational patterns of hepatitis B virus genome and clinical outcomes after emergence of drug-resistant variants during lamivudine therapy: analyses of the polymerase gene and full-length sequences.
Enomoto M; Tamori A; Kohmoto MT; Morikawa H; Habu D; Sakaguchi H; Takeda T; Seki S; Kawada N; Shiomi S; Nishiguchi S
J Med Virol; 2007 Nov; 79(11):1664-70. PubMed ID: 17854034
[TBL] [Abstract][Full Text] [Related]
3. No benefit to continue lamivudine therapy after emergence of YMDD mutations.
Liaw YF; Chien RN; Yeh CT
Antivir Ther; 2004 Apr; 9(2):257-62. PubMed ID: 15134188
[TBL] [Abstract][Full Text] [Related]
4. Mutations associated with lamivudine-resistance in therapy-naïve hepatitis B virus (HBV) infected patients with and without HIV co-infection: implications for antiretroviral therapy in HBV and HIV co-infected South African patients.
Selabe SG; Lukhwareni A; Song E; Leeuw YG; Burnett RJ; Mphahlele MJ
J Med Virol; 2007 Nov; 79(11):1650-4. PubMed ID: 17854040
[TBL] [Abstract][Full Text] [Related]
5. [Lamivudine therapy for chronic hepatitis B].
Daikoku M; Koga M
Nihon Rinsho; 2004 Aug; 62 Suppl 8():321-5. PubMed ID: 15453338
[No Abstract] [Full Text] [Related]
6. [Detection of lamivudine-resistant hepatitis B virus].
Matsumura M
Nihon Rinsho; 2004 Aug; 62 Suppl 8():175-9. PubMed ID: 15453310
[No Abstract] [Full Text] [Related]
7. [Efficacy and problems in combination therapy using lamivudine and interferon for chronic hepatitis B].
Saito T; Watanabe H; Togashi H; Kawata S
Nihon Rinsho; 2004 Aug; 62 Suppl 8():326-30. PubMed ID: 15453339
[No Abstract] [Full Text] [Related]
8. Clinical and virological features of non-breakthrough and severe exacerbation due to lamivudine-resistant hepatitis B virus mutants.
Suzuki F; Akuta N; Suzuki Y; Sezaki H; Arase Y; Hosaka T; Someya T; Kobayashi M; Saitoh S; Ikeda K; Kobayashi M; Matsuda M; Satoh J; Watahiki S; Kumada H
J Med Virol; 2006 Mar; 78(3):341-52. PubMed ID: 16419116
[TBL] [Abstract][Full Text] [Related]
9. The clinical impact of early detection of the YMDD mutant on the outcomes of long-term lamivudine therapy in patients with chronic hepatitis B.
Paik YH; Han KH; Hong SP; Lee HW; Lee KS; Kim SO; Shin JE; Ahn SH; Chon CY; Moon YM
Antivir Ther; 2006; 11(4):447-55. PubMed ID: 16856618
[TBL] [Abstract][Full Text] [Related]
10. Association between lamivudine sensitivity and the number of substitutions in the reverse transcriptase region of the hepatitis B virus polymerase.
Fukai K; Zhang KY; Imazeki F; Kurihara T; Mikata R; Yokosuka O
J Viral Hepat; 2007 Sep; 14(9):661-6. PubMed ID: 17697019
[TBL] [Abstract][Full Text] [Related]
11. Simultaneous detection of two major lamivudine-resistant mutants using competitively differentiated-PCR.
Peng XM; Gu L; Huang YS; Ma HH; Xie QF; Li G; Gao ZL
J Virol Methods; 2005 Sep; 128(1-2):168-75. PubMed ID: 15950294
[TBL] [Abstract][Full Text] [Related]
12. Virus and transaminase levels determine the emergence of drug resistance during long-term lamivudine therapy in chronic hepatitis B.
Chang ML; Chien RN; Yeh CT; Liaw YF
J Hepatol; 2005 Jul; 43(1):72-7. PubMed ID: 15896869
[TBL] [Abstract][Full Text] [Related]
13. Hepatitis B virus (HBV) genotype and YMDD motif mutation profile among patients infected with HBV and untreated with lamivudine.
Amini-Bavil-Olyaee S; Hosseini SY; Sabahi F; Alavian SM
Int J Infect Dis; 2008 Jan; 12(1):83-7. PubMed ID: 17698384
[TBL] [Abstract][Full Text] [Related]
14. Variability of reverse transcriptase and overlapping S gene in hepatitis B virus isolates from untreated and lamivudine-resistant chronic hepatitis B patients.
Pollicino T; Isgrò G; Di Stefano R; Ferraro D; Maimone S; Brancatelli S; Squadrito G; Di Marco V; Craxì A; Raimondo G
Antivir Ther; 2009; 14(5):649-54. PubMed ID: 19704167
[TBL] [Abstract][Full Text] [Related]
15. Hepatitis B virus mutations associated with antiviral therapy.
Bartholomeusz A; Locarnini S
J Med Virol; 2006; 78 Suppl 1():S52-5. PubMed ID: 16622878
[TBL] [Abstract][Full Text] [Related]
16. Comparison of hepatitis B virus subgenotypes in patients with acute and chronic hepatitis B and absence of lamivudine-resistant strains in acute hepatitis B in Japan.
Hayashi K; Katano Y; Takeda Y; Honda T; Ishigami M; Itoh A; Hirooka Y; Nakano I; Yano M; Goto H; Yoshioka K; Toyoda H; Kumada T
J Med Virol; 2007 Apr; 79(4):366-73. PubMed ID: 17311332
[TBL] [Abstract][Full Text] [Related]
17. Genotypic resistance to lamivudine among hepatitis B virus isolates in Mexico.
Alvarado-Esquivel C; de la Ascensión Carrera-Gracia M; Conde-González CJ; Juárez-Figueroa L; Ruiz-Maya L; Aguilar-Benavides S; Torres-Valenzuela A; Sablon E
J Antimicrob Chemother; 2006 Feb; 57(2):221-3. PubMed ID: 16373428
[TBL] [Abstract][Full Text] [Related]
18. [Variants and quasispecies of reverse transcriptase region in polymerase gene of hepatitis B virus during lamivudine treatment].
Tian GB; Zeng Z; Huang ZH; Lu HY; Yu M; Gong WB; Wang D; Si CW
Zhonghua Shi Yan He Lin Chuang Bing Du Xue Za Zhi; 2011 Feb; 25(1):23-5. PubMed ID: 21789847
[TBL] [Abstract][Full Text] [Related]
19. [Evolution of hepatitis B virus quasispecies during lamivudine-entecavir sequential therapy].
Liu L; Tang YZ; Li JG; Zhou JJ; Wang XH; Wang YM
Zhonghua Gan Zang Bing Za Zhi; 2010 Jun; 18(6):423-7. PubMed ID: 20587311
[TBL] [Abstract][Full Text] [Related]
20. Failure of the lamivudine-resistant rtM204I hepatitis B virus mutants to efficiently support hepatitis delta virus secretion.
Vietheer PT; Netter HJ; Sozzi T; Bartholomeusz A
J Virol; 2005 May; 79(10):6570-3. PubMed ID: 15858045
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
